Enzon Pharmaceuticals (OTCMKTS:ENZN) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.50 and traded as high as $5.7975. Enzon Pharmaceuticals shares last traded at $5.7975, with a volume of 762 shares traded.

Enzon Pharmaceuticals Price Performance

The company’s 50 day moving average is $6.05 and its 200 day moving average is $5.50. The company has a current ratio of 2.01, a quick ratio of 1.16 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $4.29 million, a price-to-earnings ratio of -0.85 and a beta of -0.03.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The company had revenue of $86.54 million for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.